Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20436993 | 0.94 | ESR1 (0.43) | ESR1ESR2CA2DEGS1 | |
| SCHEMBL2429377 | 0.87 | ESR1 (0.47) | ESR1ESR2CA2ALDH1A1LMNA | |
| SCHEMBL6810902 | 0.82 | ESR1 (0.47) | ESR1ESR2LTA4HALDH1A1LMNA | |
| SCHEMBL9406017 | 0.80 | PTGS2 (0.50) | ESR1ESR2LTA4HALDH1A1LMNA | |
| SCHEMBL29216735 | 0.80 | HRH1 (0.50) | ESR1ESR2ALDH1A1 | |
| SCHEMBL19309207 | 0.79 | PTGS2 (0.53) | ESR1ESR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL1924446 | 0.78 | — | — | |
| SCHEMBL8665678 | 0.78 | CCR1 (0.41) | ALDH1A1 | |
| SCHEMBL18076939 | 0.78 | DAO (0.44) | CYP11B1CYP11B2 | |
| SCHEMBL3515320 | 0.78 | CYP11B1 (0.41) | ALDH1A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | ESR1 2718/4885ESR2 1489/4885CA2 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.